FiercePharmaAsia—Gardasil’s Chinese approval, Lupin’s financials, CANbridge’s $25M series B
admin 26th May 2017 Uncategorised 0Merck’s HPV shot Gardasil is set for a head-to-head competition with GSK’s Cervarix in China, Lupin’s Q4 sales in North America fell 13%, China’s CANbridge gained a $25M series B to advance immunotherapies, and more.
More: FiercePharmaAsia—Gardasil’s Chinese approval, Lupin’s financials, CANbridge’s M series B
Source: fierce